Please login to the form below

Not currently logged in

GSK eyes £6bn from new product sales by 2020

Plans to file up to 20 new drugs by 2020

GlaxoSmithKline (GSK) says recent product launches and a stream of new products from its 40-candidate clinical pipeline will contribute "at least £6bn" to sales in 2020.

Discussing GSK's R&D pipeline with investors yesterday, chief executive Sir Andrew Witty said that the company intends to file for approval of up to 20 new drugs by 2020, and that around 80% of these have the potential to be first-in-class products with novel mechanisms of action.

GSK also has the potential to start phase II trials for around 30 new molecular entities (NMEs) and product line extensions and phase III studies for another 20 projects.

Among the late-stage product candidates profiled during the presentation were interleukin-5 inhibitor Nucala (mepolizumab) for severe asthma, shingles vaccine Shingrix, sirukumab for rheumatoid arthritis and daprodustat for anaemia.

Company executives also highlighted GSK's anti-infectives pipeline - including long-acting integrase inhibitor cabotegravir and broadly neutralising antibodies (bnAbs) in development at its ViiV subsidiary - which are both part of a programme to develop HIV therapies with infrequent dosing.

GSK has just announced the results of a study combining a long-acting injectable formulation of cabotegravir with Johnson & Johnson's Edurant (rilpivirine) - given every four to six weeks, which showed the combination was as effective in suppressing HIV as a three-drug oral regimen.

The company also focused during the meeting on novel antibacterial gepotidacin, a combination vaccine for the prevention of bacterial meningitis and GSK2269557, a new inhaled therapy for chronic obstructive pulmonary disease (COPD).

It unveiled a new alliance with Regulus for the development of hepatitis C virus (HCV) therapy RG-101, as well as a collaboration with Merck & Co to test GSK's OX40 agonist GSK3174998 in combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), already on the market for melanoma and lung cancer.

GSK has also been working on reducing the cost of its R&D operations, and says it has reduced its headcount from 12,000 to 8,500 since 2008 and is now conducting clinical trials 20% faster, said Sir Andrew.

He would not however be drawn on the subject of M&A - and specifically rumours that Pfizer has made an approach to GSK as well as being in negotiations with Allergan.

Sir Andrew said he was confident in GSK's ability to deliver "very substantial sales growth momentum over the next five, 10, and 15 years."  

Article by
Phil Taylor

4th November 2015

From: Sales



Subscribe to our email news alerts

Featured jobs


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....